Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001905552 | SCV002155807 | uncertain significance | Chuvash polycythemia; Von Hippel-Lindau syndrome | 2023-09-18 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt VHL protein function. ClinVar contains an entry for this variant (Variation ID: 1385557). This variant has not been reported in the literature in individuals affected with VHL-related conditions. This variant is present in population databases (rs768390987, gnomAD 0.01%). This sequence change replaces tyrosine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 185 of the VHL protein (p.Tyr185Asn). |
Baylor Genetics | RCV003470996 | SCV004206474 | uncertain significance | Chuvash polycythemia | 2023-10-06 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV004785360 | SCV005407482 | likely benign | Von Hippel-Lindau syndrome | 2024-08-26 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |